AZNのチャート
AZNの企業情報
| symbol | AZN |
|---|---|
| 会社名 | AstraZeneca Plc （アストラゼネカ） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | アストラゼネカ（AstraZeneca PLC）はグローバルな生物医薬会社である。同社は心臓血管、胃腸、感染症、神経科学、腫瘍学及び呼吸・炎症の６つ健康分野向けに処方薬の発見・開発及び商業化を行う。同社は抗生剤などの病気治療薬、酸関連疾患治療用の｢Merrem/Meronem｣及び｢Losec/Prilosec｣を含む各種薬剤を提供する。同社商品には｢Crestor｣、｢Atacand｣、｢Seloken/Toprol-XL｣、｢Plendil｣、｢Onglyza｣、｢Zestril｣、｢Symbicort｣及び｢Zoladex｣等がある。同社は世界中で複数の研究開発(R&D)施設、生産販売施設を保有・運営する。同社は中国、メキシコ、ブラジル及びロシア等100以上の国で事業を展開している。平成23年8月31日、同社はDENTSPLY International IncへのAstra Tech事業の売却を完了した。 アストラゼネカはイギリスの大手製薬企業。循環器、消化器、感染症、神経科学、腫瘍、呼吸器関連の医療用医薬品を提供。中国、ブラジル、インド、ロシアなどの新興諸国を含む100カ国超で事業を展開。主要製品は乳がん治療薬、高コレステロ―ル症治療薬、抗精神病薬、喘息治療薬、心不全治療薬、前立腺がん治療薬、高血圧・狭心症治療薬など。本社はロンドン。 |
| 本社所在地 | 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA GBR |
| 代表者氏名 | Pascal Soriot |
| 代表者役職名 | Executive Director and Chief Executive Officer |
| 電話番号 | +44 20-7304-5000 |
| 設立年月日 | 33756 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 64400人 |
| url | www.astrazeneca.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） 7777.00000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 105410.40000 |
| 売上高 | （百万ドル） 22090.00000 |
| 企業価値(EV) | （百万ドル） 118843.40000 |
| 当期純利益 | （百万ドル） 2155.00000 |
| 決算概要 | BRIEF: For the fiscal year ended 31 December 2018 AstraZeneca plc (ADR) revenues decreased 2% to $22.09B. Net income before extraordinary items decreased 10% to $2.16B. Revenues reflect United Kingdom segment decrease of 26% to $2.39B Sweden segment decrease of 43% to $477M Japan segment decrease of 10% to $1.95B. Net income also reflects The Americas segment loss totaling $757M vs. income of $1.24B Other Asia. |
AZNのテクニカル分析
AZNのニュース
Has the Oxford vaccine been approved for use in the UK yet? 2020/12/15 16:23:57 Manchester Evening News
The University of Oxford and AstraZeneca's vaccine candidate was a front-runner in the global race to produce a vaccine against Covid-19
Brasil espera la vacuna de Astrazeneca para poder inmunizar 2020/12/15 10:50:21 Publico
En el mejor de los escenarios en Brasil la vacunación empezaría en marzo. La apuesta brasileña es la vacuna de Oxford Astrazeneca con quien firmó un acuerdo para asegurarse la materia prima y la transferencia de tecnologia para que el instituto Fiocruz, con sede en Río de Janeiro, produzca las dosis. Esperan poder administrar 100 millones de dosis en la primera mitad de 2021 y otros 110 millones de dosis en la segunda mitad. Ese plazo depende de la aprobación del regulador de salud brasileño. Pendientes de la llegada de la vacuna, en Brasil el COVID sigue causando estragos con más de 180 mil muertos.
Currency rates for Dec. 15 2020/12/15 08:45:00 AzerNews
The official exchange rate of the US dollar and euro against Azerbaijani manat was set at 1.7 manat and 2.0652 manat respectively for Dec.15.
Anxiety and Panic Disorders Drugs Market Research Report (2020-2026): Key Trends and Opportunities |AstraZeneca, Eli Lilly, GlaxoSmithKline, Pfizer 2020/12/15 08:17:19 OpenPR
The global Anxiety and Panic Disorders Drugs market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the
El fracaso de Sanofi podría retrasar los planes de vacunación del Gobierno 2020/12/15 05:11:32 El Pais Cinco Dias
AstraZeneca y Janssen, cruciales ahora para lograr la inmunidad de grupo Novavax podría sumar dosis si cierra un acuerdo con Bruselas
This group will compare every coronavirus vaccine and tell us which ones are the best 2020/10/02 23:15:38 BGR
Coronavirus vaccines have been a sensitive topic in recent months. The highly politicized discussions around vaccines in the US have eroded the public’s trust in these key COVID-19 drugs. An organization aims to compare “apples to apples” and analyze data from all of the experimental drugs that reach clinical trials to determine which COVID-19 vaccine candidates have the best chances of beating the virus. The Coalition for Epidemic Preparedness Innovations (CEPI), which is funding in part some of the vaccines that are in late-stage testing, has set up a network of labs to begin analyzing data from the separate coronavirus vaccine trials running around the world. Several coronavirus vaccines are in the last stage of the human trials, and we’ll have the final conclusions from some of these frontrunners in the coming months. But as these experimental drugs have been increasingly politicized, especially in the US with the presidential election looming, the public’s trust in drugs that were developed faster than ever has eroded.
Canada is reviewing its first COVID-19 vaccine application. Here’s what that means 2020/10/02 22:31:48 The Star
AstraZeneca has applied for Canadian regulatory approval for the so-called Oxford vaccine, becoming the first company to do so. But don’t expect a finished vaccine just yet
News24.com | Leading Covid-19 vaccine trial resumes in Japan but not US 2020/10/02 20:33:27 News24
Trials on the coronavirus vaccine developed by AstraZeneca and Oxford University have resumed in Japan but not the United States, where the pharmaceutical giant is working with regulators, a statement released said.
Moderna, Pfizer & BioNTech, and AstraZeneca and the University of Oxford's COVID-19 Vaccine Trials are Entering the Final Stage of Development 2020/10/02 19:30:00 PR Newswire
DUBLIN, Oct. 2, 2020 /PRNewswire/ -- ResearchAndMarkets.com published a new article on the vaccine industry "COVID-19 Vaccine Trials are Entering the Final Stage of Development" Johnson & Johnson has begun final stage testing of its COVID-19 vaccine candidate. The company will trial the…
Canada to Begin Review of AstraZeneca COVID-19 Vaccine Amid Immunization Skepticism 2020/10/02 17:35:22 UrduPoint
España se suma a la compra centralizada de la UE de la vacuna de AstraZeneca 2020/08/25 12:59:57 La Vanguardia
España, junto con otros Estados miembros, se ha sumado a la compra centralizada de la Comisión Europea (CE) de millones de dosis de una futura vacuna contra la COVID-19 de la farmacéutica británica AstraZeneca, que está desarrollando…
Pharmaceutical giant AstraZeneca gives first doses to patients in Covid-19 treatment trial 2020/08/25 12:32:41 TheJournal IE
The pharmaceutical giant hopes the drug will act as a preventative for people exposed to the virus, as well as to treat patients with Covid-19.
AstraZeneca starts UK COVID-19 drug trial 2020/08/25 11:33:47 Inquirer News Info
Pharma giant AstraZeneca said Tuesday it had begun a clinical trial of a drug designed to both prevent infection and treat people with COVID-19, with the first volunteers receiving doses. The drug, known as AZD7442, is a combination of two antibodies and is being tested on 48 healthy people aged between 18 and 55, the company said. "This trial is an important milestone in the development of our monoclonal antibody combination to prevent or treat COVID-19," said Mene Pangalos, executive vice-president of biopharmaceuticals research and development at AstraZeneca. The company said the trial would help evaluate the safety of the drug and be used both to prevent the disease and … Keep on reading: AstraZeneca starts UK COVID-19 drug trial
España se suma a la compra centralizada de la Comisión Europea de la vacuna de Astrazeneca 2020/08/25 10:12:00 La Cerca
Esta vacuna es una de las alternativas más avanzadas y está ya llevando a cabo ensayos clínicos para garantizar su seguridad y eficacia. España, junto con otros Estados miembros, se ha sumado a la compra de esta vacuna. El reparto se hará de manera equitativa entre los países acorde a su población.